Home > Journals > Giornale Italiano di Dermatologia e Venereologia > Past Issues > Giornale Italiano di Dermatologia e Venereologia 2008 December;143(6) > Giornale Italiano di Dermatologia e Venereologia 2008 December;143(6):395-408

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA

A Journal on Dermatology and Sexually Transmitted Diseases


Official Journal of the Italian Society of Dermatology and Sexually Transmitted Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,311


eTOC

 

REVIEWS  


Giornale Italiano di Dermatologia e Venereologia 2008 December;143(6):395-408

Copyright © 2008 EDIZIONI MINERVA MEDICA

language: English

The treatment of mycosis fungoides

Sebastian Mestel D. 1, Beyer M. 1, Steinhoff M. 1, Sterry W. 1, Assaf C. 1, 2

1 Department of Dermatology and Allergy Skin Cancer Center Charité-Universitaetsmedizin, Berlin, Germany 2 Department of Dermatology and Venerology HELIOS Klinikum Krefeld, Germany


PDF  


Primary cutaneous T-cell lymphomas (PCLs) mycosis fungoides (MF) and Sézary syndrome (Ss) belong to the group of non-Hodgkin lymphomas (NHL), which are characterized by clonally proliferating CD4+ cells localized in the skin. Although there already exist many conventional skin-directed and systemic cytotoxic treatment options, in long-term only a transient remission without curative results will be reached in most cases. The aim of this article was to present actual assumed treatment modalities, as well as new therapeutic strategies which passed already through clinical trials showing promising results in the treatment of PCLs.

top of page

Publication History

Cite this article as

Corresponding author e-mail